Dabid Under the Microscope: Dr Abidi Pharmaceutical's Six-Month Profit Jumped 3.3x; Dissecting a Surge That Didn't Come From Sales Alone (Saturday, 18 July 2026)
Sahmino Research Desk | 18 July 2026 | Short | 01:27
Watch onSahmino
Mid-session today, Dr Abidi Pharmaceutical (Dabid) published its unaudited six-month statements: revenue grew 118% to 13.2 thousand billion tomans, the operating margin jumped to 50.2%, and net profit reached 3.3x at an EPS of 939 rials. A dissection shows four engines behind the jump, but three questions stay open: the cash backing of profit, the price-versus-volume split, and the nature of 958 billion tomans of non-operating income.
Related videos
Farabi Pharma's Six-Month Profit Passed Its Whole Prior Year, but Operating Cash Is 37.6% of Profit; Entry Holds Up to 21,273 Rial (Monday 2 November 2026)
Short | 00:47StocksGhachar Under the Lens: Chaharmahal Sugar's Sales Rose 50% and Profit 43% in FY1404; But Through the Inflation Lens, Real Growth Is Near Zero (Saturday, 18 July 2026)
Short | 01:27StocksVomelal Under the Lens: A 14.3-Trillion-Toman Net Loss and Negative 59% Capital Adequacy; Why Conventional Valuation Tools Fail for Mellal Credit Institution (Saturday, July 18, 2026)
Short | 01:32StocksVomodir Under the Lens: A 17,346 Billion Rial Net Profit and a Price to Earnings of 3.2; Why the Market Prices the Pension Fund Holding at a Discount (Saturday, 18 July 2026)
Short | 01:35Stocks




